Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Trimethylamine-N-oxide (TMAO) and risk of incident cardiovascular events in the multi ethnic study of Atherosclerosis

Budoff MJ, de Oliveira Otto MC, Li XS, Lee Y, Wang M, Lai HTM, Lemaitre RN, Pratt A, Tang WHW, Psaty BM, Siscovick DS, Hazen[...]

Exploring depression treatment response by using polygenic risk scoring across diverse populations

Lapinska S, Pimplaskar A, Shi Z, Ding Y, Frydman-Gani C, Hou K, Venkateswaran V, Boulier K, Olde Loohuis LM, Pasaniuc B. Exploring depression treatment response[...]

A molecular tango between chromatin and metabolites orchestrates a feedback switch for alcohol consumption

Schmidt HM, Tarling EJ, Vallim TQA. A molecular tango between chromatin and metabolites orchestrates a feedback switch for alcohol consumption. Proc Natl Acad Sci U[...]